536 related articles for article (PubMed ID: 37966683)
1. Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.
Ansari MA; Tripathi T; Venkidasamy B; Monziani A; Rajakumar G; Alomary MN; Alyahya SA; Onimus O; D'souza N; Barkat MA; Al-Suhaimi EA; Samynathan R; Thiruvengadam M
Mol Neurobiol; 2024 May; 61(5):3042-3089. PubMed ID: 37966683
[TBL] [Abstract][Full Text] [Related]
2. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.
Masoudi Asil S; Ahlawat J; Guillama Barroso G; Narayan M
Biomater Sci; 2020 Aug; 8(15):4109-4128. PubMed ID: 32638706
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.
Nguyen-Thi PT; Ho TT; Nguyen TT; Vo GV
Curr Drug Deliv; 2024; 21(7):917-931. PubMed ID: 37424345
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Nanocarrier for Synergistic Treatment of Alzheimer's Disease by Inhibiting β-Amyloid Aggregation and Scavenging Reactive Oxygen Species.
Wang C; Song X; Li P; Sun S; Su J; Liu S; Wei W
ACS Appl Mater Interfaces; 2024 May; 16(21):27127-27138. PubMed ID: 38747495
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease.
Karthivashan G; Ganesan P; Park SY; Kim JS; Choi DK
Drug Deliv; 2018 Nov; 25(1):307-320. PubMed ID: 29350055
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems.
Poudel P; Park S
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456671
[TBL] [Abstract][Full Text] [Related]
7. Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders.
Naimi N; Seyedmirzaei H; Hassannejad Z; Soltani Khaboushan A
Biomed Pharmacother; 2024 Jun; 175():116691. PubMed ID: 38713941
[TBL] [Abstract][Full Text] [Related]
8. Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders.
Nguyen TT; Nguyen TTD; Tran NM; Van Vo G
Neurochem Res; 2022 Mar; 47(3):552-573. PubMed ID: 34800247
[TBL] [Abstract][Full Text] [Related]
9. Development of nanomedicines for the treatment of Alzheimer's disease: Raison d'être, strategies, challenges and regulatory aspects.
Mazahir F; Alam MI; Yadav AK
Ageing Res Rev; 2024 Jul; 98():102318. PubMed ID: 38705362
[TBL] [Abstract][Full Text] [Related]
10. Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.
Rhaman MM; Islam MR; Akash S; Mim M; Noor Alam M; Nepovimova E; Valis M; Kuca K; Sharma R
Front Cell Dev Biol; 2022; 10():989471. PubMed ID: 36120565
[TBL] [Abstract][Full Text] [Related]
11. Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management.
Siddiqi KS; Husen A; Sohrab SS; Yassin MO
Nanoscale Res Lett; 2018 Aug; 13(1):231. PubMed ID: 30097809
[TBL] [Abstract][Full Text] [Related]
12. Brain Targeting Nanomedicines: Pitfalls and Promise.
Kakinen A; Jiang Y; Davis TP; Teesalu T; Saarma M
Int J Nanomedicine; 2024; 19():4857-4875. PubMed ID: 38828195
[TBL] [Abstract][Full Text] [Related]
13. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective Effects of Curcumin in Neurodegenerative Diseases.
Genchi G; Lauria G; Catalano A; Carocci A; Sinicropi MS
Foods; 2024 Jun; 13(11):. PubMed ID: 38891002
[TBL] [Abstract][Full Text] [Related]
15. Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.
Fatima J; Siddique YH
CNS Neurol Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38288843
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Membrane-Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease.
Lin RR; Jin LL; Xue YY; Zhang ZS; Huang HF; Chen DF; Liu Q; Mao ZW; Wu ZY; Tao QQ
Adv Sci (Weinh); 2024 Jun; 11(24):e2306675. PubMed ID: 38647399
[TBL] [Abstract][Full Text] [Related]
17. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
18. Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems.
Kaur K; Kulkarni YA; Wairkar S
Brain Res; 2024 Jul; 1834():148905. PubMed ID: 38565372
[TBL] [Abstract][Full Text] [Related]
19. Nanotheranostic agents for neurodegenerative diseases.
Padmanabhan P; Palanivel M; Kumar A; Máthé D; Radda GK; Lim KL; Gulyás B
Emerg Top Life Sci; 2020 Dec; 4(6):645-675. PubMed ID: 33320185
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
Siafaka PI; Mutlu G; Okur NÜ
Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
